Any diabetic that that reads that article will want Afrezza over traditional insulin therapy. Great find.

My Bydureon is $3960 per year.

Please help me out. There are no earnings so is it just the fiancial health (money left for operating) that is the real interest. Thanks.

Bydureon is a great drug and the benefits to me outway the risk. Last A1c came in at 6.4.

The shot is not a big deal although mixing is involved and an occassional clogged needle means a second injection. I've been on it 4.5 years including 3 on a phase 3 trial.

It is my nderstanding that a premixed pen would be available sometime in late 2013. I still don't see this as a reason to add to their salesforce. Although they have had lacluster sales with Budureon I can't bellieve they would add 450 new reps for just Bydureon. I am not inclined to suggest they are adding because they will partner with MNKD, but perhaps they intend to make a full court press with their entire diabeties lines.

I have been on Bydureon for 4.5 years and it is a great drug. Last A1c came in at 6.4. I am convinced that lawyers read the side affects of drugs on the labels and then troll for people who may have experienced them. The lawyers create a feeding frenzy and the FDA does the politically correct thing by launching an investigation. It is maddening to see the legal profession reduced to a swarm of pirahana. You can bet that after Afrezza is approved there will be lawsuits claiming lung issues including cancer. Just goes with the territory in todays world.

Could MNKD be sold with a stipulation that the name be retained as Mannkind a Division of XXXXXXXXXX ?